000766.SZ
000766.SZ
CNE000000735
TONGHUA GOLDEN HORSE
Loading chart...

Company Profile

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of pharmaceutical products in China. The company provides anti-tumor drugs, gynecological medications, medication for rheumatic bone pain, urological medications, heat-clearing and detoxifying drugs, cardiovascular and cerebrovascular drugs, digestive medications, tonifying and restorative medicines, respiratory medication, diabetes medication, ENT medication, and pediatric medications. It also offers Xiaojin pills, Tian Ranshexiang Xiaojin pills, Xiaokechuan capsules, Jiuwei Qianghuo granules, Xiongdan powder, Bear Bile powder, and Wenweishu tablets to treat glandular hyperplasia, inflammatory diseases, bone trauma and soft tissue injury, and other related diseases. In addition, the company provides bacillus cereus live bacteria capsules, bacillus cereus live bacteria tablets are therapeutic live bacteria microecological preparations to treat enteritis, diarrhea, infantile diarrhea, and intestinal dysfunction. The company was founded in 1990 and is headquartered in Tonghua, China.

Related stocks

300601.SZ
300601.SZ • China
KANGTAI BIOLOGICAL
13.44 CNY
2.25B USD 1Y -20.6%
300363.SZ
300363.SZ • China
PORTON
23.68 CNY
1.93B USD 1Y -9.3%
603707.SS
603707.SS • China
NANJING KING-FRIEND BIOCHEMICAL
8.18 CNY
1.98B USD 1Y -21.6%
600518.SS
600518.SS • China
KANGMEI PHARMACEUTICAL CO LTD
1.35 CNY
2.79B USD 1Y -33.8%
300725.SZ
300725.SZ • China
PHARMABLOCK
51.01 CNY
1.78B USD 1Y +22.3%
300723.SZ
300723.SZ • China
YPH
33.42 CNY
2.26B USD 1Y -40.6%
000623.SZ
000623.SZ • China
JLAD
17.53 CNY
3.14B USD 1Y -13.7%
300558.SZ
300558.SZ • China
BETTA
48.43 CNY
3.07B USD 1Y -29.3%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
51.5% p.a.
Max Drawdown (5Y)
-51.3%
Sharpe Ratio (5Y)
0.52
Beta Factor
0.53
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
🔴 High valuation risk: Avg P/E of 499.0 (Elevated multiple compression risk)
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (51.5% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -86.2% in the extended horizon.
ende